Vitiligo is quite a common hypopigmentary disorder, which may affect both children and adults with important psychological effects due to the well-known leopard skin-like appearance. The authors summarize in the present study the published evidence on vitiligo with particular interest on the controversial aspects of the disease, such as its definition and the available treatments.
| INTRODUCTION
Vitiligo is the most common acquired cutaneous hypomelanosis, affecting approximately 0,5-1% of the world's population, with serious cosmetic and psychological effects (Ezzedine et al., 2012) . No less important is the emerging concept that vitiligo may be associated with other different diseases, underlining how it could be considered not as a singular dermatological disorder but as a systemic disease (Colucci et al., 2014; Lotti & D'erme, 2014) .
Although its etiopathology is not fully elucidated, it seems to be the result of an autoimmune process. This pigmentary disorder is characterized by white macules and patches, due to the progressive loss of cutaneous melanocytes and to an abnormality in their normal function. The characteristic depigmentation can be restricted to a limited skin area (segmental vitiligo, focal vitiligo, and follicular vitiligo) or generalized in symmetrical patches (nonsegmental vitiligo).
Today new different kinds of therapies, both medical and surgical, are available, but none of them may be considered as a standard gold treatment for the variable results in term of repigmentation and the risk of side effects .
| INNOVATIVE AND PROMISING TREATMENTS-SELECTED CONCEPTS
2.1 | Phototherapy (PUVA therapy, topical PUVA, bath PUVA and narrow-band UVB, microfocused nb-UVB, UVA1 laser)
The efficacy of ultraviolet radiations in the treatment of vitiligo has long been a well-known therapy. Even today, phototherapies are considered a first line therapy, especially for extensive vitiligo, because of their good efficacy and tolerance. The effects of UVR are both immunosuppression and stimulation of the melanocytes activity (Gianfaldoni, Zarrab, & Lotti, 2014) . Between these options, narrowband UVB (nb-UVB, 311 nm) is considered the most valid and safest therapy of vitiligo, due to the lack of psoralens. Among the different therapeutic protocols based on the use of nb-UVB, alone or associated with different treatments, the most innovative is the microfocused phototherapy which consists only in the treatment of skin lesions, limiting the side effects, and allowing the possibility of achieving faster and better clinical results. Even if different devices are now available with this purpose, such as excimer lasers or bioskin, maybe one of the most interesting innovation is the selective sunlight therapy, which consists in the topical application, onto skin lesions, of a cream that filters UVR in order to obtain only nb-UBV . Recently, another phototherapeutic modality has been introduced: the focused UVA1 radiation therapy. This treatment seems to be safe and effective. In detail, its association with Fraxel Herbium laser, topical Latanoprost solution seems to provide better clinical results in term of repigmentation rates, without side effects. .
| Low dose cytokines
Many studies underline how vitiligo is characterized by an unbalance of the signaling molecules (e.g., growth factors and cytokines) that regulate the normal cross talk between keratinocytes and melanocytes. A recent systematic review (Gomes et al., 2018) 
| Antioxidants
In the last decades, a deeper attention has been directed to the pathogenic mechanism of vitiligo progression and in particular to the role of oxidative stress (Prignano et al., 2009; Lotti et al., 2015a; Lotti et al., 2015b) . Among the mechanisms that have been proposed for the pre- As dermatologists, we have two goals in the treatment of vitiligo patients: the first one is to halt the disease progression, the second one is to induce the repigmentation of the lesions, achieving an acceptable cosmetic result. In the last years, several therapeutic options, both medical and surgical, have been proposed for vitiligo.
The last questions are: is there any safe, systemic, and effective treatment for vitiligo? Which is the most effective and safest treatment (local and systemic) of depigmented skin? Unfortunately, at the moment no gold standard treatments are available. The choice of the best therapy for adult and childhood vitiligo is based on various factors, such as the patient's age, psychological condition and expectation, distribution and extension of skin lesions, type of vitiligo (stable or not), availability, and cost of therapeutic options.
As in other dermatologic conditions (e.g., psoriasis, atopic dermatitis, or hidradenitis suppurativa), target therapies and innovative treatments are on the way in order to brighten the future of patients with vitiligo.
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